213Bi-C595

213Bi-C595 is a radiolabeled monoclonal antibody drug consisting of the murine monoclonal antibody C595, which targets the MUC1 antigen, conjugated with the alpha-emitting radionuclide bismuth-213 via a chelator (often cDTPA). The drug is designed to specifically bind to cells expressing high levels of MUC1, a transmembrane glycoprotein overexpressed in several cancers including pancreatic and ovarian carcinomas. Upon binding to MUC1, the radioconjugate delivers potent cytotoxic alpha particle radiation, inducing DNA double-strand breaks and triggering apoptosis in targeted cancer cells. Preclinical studies have shown that 213Bi-C595 is highly cytotoxic to MUC1-positive tumor cells in a concentration-dependent manner and can significantly prolong survival in animal models of pancreatic and ovarian cancer. Its main development focus is the treatment of micrometastases or minimal residual disease in cancers with MUC1 overexpression, such as pancreatic and ovarian cancer[1][3].

Other names

213Bi-C595bismuth-213 C595bismuth213 C595bismuth 213 C595213Bi-DTPA-C595-mAb